| Name | Title | Contact Details |
|---|
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.
Afecta Pharmaceuticals is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oregon Freeze Dry, Inc. has a firm policy to produce only high quality food products in the cleanest, most modern food processing plant. Our facilities are USDA and FDA approved and are continuously inspected. We use the highest quality meat, poultry,
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Amarillo Biosciences, Inc. is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.